Coautor del trabajo titulado - Butyrate treatment during gestation prevents metabolic anomalies in mothers and fetuses

FLORENCIA HEINECKE, DAIANA FORNES, JUAN CRUZ OCCHIUZZI, ALICIA JAWERBAUM, VERÓNICA WHITE

Congreso; Inside and Out, Biochemical Society Early Career Life Scientists; 2021

Maternal obesity programs metabolic abnormalities in fetuses that precede a high susceptibility to the development of fatty liver later in life. Previously, we observed lipid overaccumulation in the fetal liver of the fatty diet group in a rat model of overweight. These alterations persisted in the adult offspring of the model. Butyrate, a short chain fatty acid product of fiber metabolism from intestinal microbiota, improves lipid homeostasis and prevents inflammation. We hypothesized that butyrate, administrated during gestation to the overweight pregnant rats, prevents metabolic anomalies in fetuses, improving the metabolic health of the offspring. Methods: Female rats were fed standard (CT rats, n=8) or standard supplemented with saturated fat diet (28% fat) since they were 6 week-old (FD rats, n=14). After 8 weeks of diet, both groups were mated with control males. FD pregnant rats were orally administrated 3% of sodium butyrate or vehicle daily during gestation (FDB rats). At gestational day 21, all rats were euthanized. Maternal and fetal plasma and liver were obtained. Triglyceridemia was assessed by colorimetric assays, measured as mg/dL. Maternal and fetal liver lipid levels of triglycerides (TG), Free Fatty Acids (FFA), Cholesterol (Ch) and Cholesterol Esters (ChE) were assessed by TLC, measured as g of lipid/mg protein. Data are presented as the mean ± standard error. Statistical differences between the groups were evaluated by one-way ANOVA test, post-test Tukey. A p value less than 0.05 was considered statistically significant: *p